The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction: A single institution retrospective experience
Author:
Publisher
Medknow
Subject
General Medicine
Reference17 articles.
1. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017;Dong;Exp Hematol Oncol,2020
2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia Version 3; 2020. Available from: https://www.nccn.org/professional s/physician_gls/pdf/aml.pdf [Last accessed on 2020 Dec 05].
3. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?;Ofran;Curr Opin Hematol,2016
4. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia;Ofran;Am J Hematol,2015
5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessment of Complete Remission Rate in Patients with Acute Myeloid Leukemia Undergoing 7+3 Induction Chemotherapy;Pakistan Journal of Health Sciences;2024-06-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3